Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results

Fourth-Quarter and Full-Year 2019 Financial Results Driven by Strong Orphan and Rheumatology Segment Growth ($M, except for per share amounts) Net sales Net income (loss) Non-GAAP net income Adjusted EBITDA Earnings (loss) per share - diluted Non-GAAP earnings per share - diluted Q4 2019 Q4 2018 % Change FY 2019 FY 2018 % Change $363.5 $355.5 2 $1,300.0 $1,207.6 8 592.8 101.6 483 573.0 (38.4) NM 116.6 116.8 390.2 314.7 24 24 139.9 151.1 (7) 482.8 451.4 7 $2.84 $0.58 390 $2.90 ($0.23) NM $0.56 $0.67 (16) $1.94 $1.83 6 Note: Non-GAAP net income, adjusted EBITDA and non-GAAP earnings per share are non-GAAP measures; see reconciliations at the end of the presentation for a reconciliation of GAAP to non-GAAP measures. HI HORIZON 40

View entire presentation